When does the vonoprazan patent expire?
The primary patent for vonoprazan, which covers the compound itself, is set to expire in Japan in 2031 and in the United States in 2032. However, additional patents related to specific formulations or methods of use could extend exclusivity beyond these dates [1].
What other patents protect vonoprazan?
Beyond the main compound patent, there are numerous secondary patents covering various aspects of vonoprazan. These can include patents for different salt forms, polymorphs, manufacturing processes, and specific therapeutic uses. These secondary patents can significantly impact the market entry timeline for generic versions, as they may offer protection even after the primary patent expires [1]. DrugPatentWatch.com tracks these patents, providing insights into the intellectual property landscape surrounding vonoprazan [1].
Who is developing vonoprazan?
Vonoprazan is primarily developed and marketed by Takeda Pharmaceutical Company. It is available under brand names such as Takecab and Vocinti [2].
What is vonoprazan used to treat?
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used to treat acid-related gastrointestinal disorders. Its indications include erosive esophagitis, gastric ulcers, duodenal ulcers, and as part of combination therapy for Helicobacter pylori eradication [2][3]. It is also used for the prevention of ulcer recurrence during low-dose aspirin or NSAID administration [3].
How does vonoprazan work?
Vonoprazan inhibits the gastric H+, K+-ATPase (proton pump) by reversibly binding to the potassium ion (K+) binding site of the enzyme. This mechanism leads to rapid and sustained suppression of gastric acid secretion [3].
What are the potential risks or side effects of vonoprazan?
Common side effects associated with vonoprazan include diarrhea, constipation, nausea, abdominal pain, and rash. More serious, though less common, adverse events can occur [3].
How does vonoprazan compare to proton pump inhibitors (PPIs)?
Vonoprazan belongs to a different class of drugs (P-CABs) than traditional proton pump inhibitors (PPIs) like omeprazole or lansoprazole. P-CABs generally offer a faster onset of action and more potent acid suppression compared to PPIs, as their mechanism of action is less dependent on the activation state of the proton pump [3].
What is the regulatory status of vonoprazan in different regions?
Vonoprazan has been approved in several countries, including Japan, China, South Korea, the United States, and Europe, for various acid-related indications [2][3]. The specific approved uses and launch timelines can vary by region.
Can generic versions of vonoprazan be launched before patent expiry?
The launch of generic vonoprazan is contingent on the expiration of its relevant patents. While the compound patent provides a baseline for exclusivity, secondary patents covering formulations or manufacturing processes can delay generic entry. Challenges to these patents or potential litigation could also influence the timeline for generic availability [1].
Sources:
[1] https://www.drugpatentwatch.com/drug/vonoprazan
[2] Takeda Pharmaceutical Company, Inc. (various press releases and investor information)
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215948s004lbl.pdf